Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Per Thor Straten

Showing results (121-130 of 171) with videos related to

Pageof 18
Sort By:
Vaccine|December 18, 2004
Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivinKerstin Otto, Mads Hald Andersen, Andreas Eggert, et al.
The FEBS Journal|January 7, 2005
Towards discovery-driven translational research in breast cancerJulio E Celis, José M A Moreira, Irina Gromova, et al.
Oncoimmunology|November 20, 2019
T cell recognition of novel shared breast cancer antigens is frequently observed in peripheral blood of breast cancer patientsNadia Viborg, Sofie Ramskov, Rikke Sick Andersen, et al.
Cancer Immunology, Immunotherapy : CII|May 10, 2007
HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptidesMorgan G Mathieu, Ashley J Knights, Graham Pawelec, et al.
Journal for Immunotherapy of Cancer|November 13, 2020
Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trialJuliane Schuhmacher, Sonja Heidu, Torben Balchen, et al.
International Journal of Cancer|June 16, 2004
Circulation and homing of melanoma-reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte-derived dendritic cellsThomas G Berger, Ina Haendle, David Schrama, et al.
Plos One|December 21, 2016
(GT)n Repeat Polymorphism in Heme Oxygenase-1 (HO-1) Correlates with Clinical Outcome after Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell TransplantationTania Køllgaard, Brian Kornblit, Jesper Petersen, et al.
Cytotherapy|March 25, 2011
Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transferNiels Junker, Mads Hald Andersen, Lynn Wenandy, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 10, 2008
Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trialAnnika Berntsen, Redas Trepiakas, Lynn Wenandy, et al.
Plos One|September 10, 2009
The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenaseRikke Baek Sørensen, Linda Berge-Hansen, Niels Junker, et al.
Pageof 18

Showing results (121-130 of 171) with videos related to

Sort By:
Pageof 18
Vaccine|December 18, 2004
Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivinKerstin Otto, Mads Hald Andersen, Andreas Eggert, et al.
The FEBS Journal|January 7, 2005
Towards discovery-driven translational research in breast cancerJulio E Celis, José M A Moreira, Irina Gromova, et al.
Oncoimmunology|November 20, 2019
T cell recognition of novel shared breast cancer antigens is frequently observed in peripheral blood of breast cancer patientsNadia Viborg, Sofie Ramskov, Rikke Sick Andersen, et al.
Cancer Immunology, Immunotherapy : CII|May 10, 2007
HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptidesMorgan G Mathieu, Ashley J Knights, Graham Pawelec, et al.
Journal for Immunotherapy of Cancer|November 13, 2020
Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trialJuliane Schuhmacher, Sonja Heidu, Torben Balchen, et al.
International Journal of Cancer|June 16, 2004
Circulation and homing of melanoma-reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte-derived dendritic cellsThomas G Berger, Ina Haendle, David Schrama, et al.
Plos One|December 21, 2016
(GT)n Repeat Polymorphism in Heme Oxygenase-1 (HO-1) Correlates with Clinical Outcome after Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell TransplantationTania Køllgaard, Brian Kornblit, Jesper Petersen, et al.
Cytotherapy|March 25, 2011
Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transferNiels Junker, Mads Hald Andersen, Lynn Wenandy, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 10, 2008
Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trialAnnika Berntsen, Redas Trepiakas, Lynn Wenandy, et al.
Plos One|September 10, 2009
The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenaseRikke Baek Sørensen, Linda Berge-Hansen, Niels Junker, et al.
Pageof 18